PatchTheCVECVE-2025-29895: A NULL pointer dereference vulnerability has been reported to affect Qsync Central
CVE-2025-29895 is a low-severity flaw (CVSS 2.3) affecting affected software. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.
A NULL pointer dereference vulnerability has been reported to affect Qsync Central. If a remote attacker gains a user account, they can then exploit the vulnerability to launch a denial-of-service (DoS) attack. We have already fixed the vulnerability in the following version: Qsync Central 5.0.0.4 and later
Why this priority
- No elevated risk signals yet
No fix is published yet: follow the downgrade or mitigation steps.
Risk facts
| CVSS score | 2.3 (Low) |
| Attack vector | Network (remote) |
| Attack complexity | Low |
| Privileges needed | Low |
| User interaction | None |
| EPSS exploit chance | 0.3% (top 80%) |
| CISA exploited list | No |
| Weakness | CWE-476 |
| Published | 2026-10-15 |
| Last modified | 2026-10-19 |
Last updated 2026-10-19 · Sources: CVE Program, NVD, CISA KEV, EPSS and vendor advisories · How we score
Timeline
- Published CVE record published
- Updated Record last modified
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.
Quick answers
How do I fix CVE-2025-29895?
No fixed release is listed yet. Watch the vendor advisory and apply any mitigation shown on this page.
Is CVE-2025-29895 being exploited?
CVE-2025-29895 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.
What does CVE-2025-29895 affect?
CVE-2025-29895 affects affected software. Severity is low (CVSS 2.3). A NULL pointer dereference vulnerability has been reported to affect Qsync Central. If a remote attacker gains a user account, they can then exploit the vulnerability to launch a denial-of-service (DoS) attack. We have already fixed the vu
How urgent is CVE-2025-29895?
Priority 13/100. No elevated risk signals yet.